Accelerate to discover

Back to filter

Related topics

Top 10 Pharma companies have chosen CYTEK for their flow cytometry facility

Cytek Biosciences

Jun 21, 2021

6 of Top 10 Pharma Companies (Based on total group revenues) have chosen CYTEK - full spectrum flow cytometer for their...

Jun 21, 2021

Elevated NSD3 histone methylation activity drives squamous cell lung cancer

Spectral Instruments Imaging

Jun 8, 2021

This work identifies NSD3 as a principal 8p11-12 amplicon-associated oncogenic driver in LUSC, and suggests that...

IncuCyte webinar recording: How to measure Immune Cell Killing of Tumor Cells effectively

Sartorius

Jun 4, 2021

Immuno-oncology (IO) has transformed cancer treatment. The number of treatments in the IO pipeline continues to...

White Paper: Immunophenotyping Rare Immune Cells with Laminar Wash AUTO System

Curiox

Jun 3, 2021

The Laminar Wash (LW) AUTO system consists of a wall-less plate and a laminar flow cell washer that enable automated...

Jun 21, 2021

A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic

Tonbo Biosciences

Jun 3, 2021

Tonbo Biosciences flow cytometry reagents & antibodies are manufactured with the highest quality and precision and...

Show all topics (10)

Cancer cells resist mechanical destruction in the circulation via RhoA-myosin II axis

Mar 20, 2020

During metastasis cancer cells are exposed to potentially destructive hemodynamic forces including fluid shear stress (FSS) while en route to distant sites. However, prior work indicates that cancer cells are more resistant to brief pulses of high-level fluid shear stress (FSS) in vitro relative to non-transformed epithelial cells. Herein we identify a mechanism of FSS resistance in cancer cells, and extend these findings to mouse models of circulating tumor cells (CTCs). We show that cancer cells acutely isolated from primary tumors are resistant to FSS. Our findings demonstrate that cancer cells activate the RhoA-myosin II axis in response to FSS, which protects them from FSS-induced plasma membrane damage. Moreover, we show that the myosin II activity is protective to CTCs in mouse models. Collectively our data indicate that viable CTCs actively resist destruction by hemodynamic forces and are likely to be more mechanically robust than is commonly thought.

Do you want to learn more? Read the whole article!

Scientific paper
Application

Get more info

Miroslav Vecheta

Support specialist

Miroslav

Vecheta

+420 255 700 886

Send Message

Brand profile

Spectral Instruments Imaging

Spectral Instruments Imaging manufactures instruments for preclinical optical (bioluminescent, fluorescent) and X-ray imaging.

Related products

System for individual researchers and smaller specialist teams to conduct optical imaging studies in disease model progression, response to therapy, and cell migration in-vivo.

show detail

The Ami HT and Ami HTX (includes X-Ray imaging) optical imaging systems establish a new, high throughput benchmark for in vivo imaging suitable for specialist researchers and small teams.

show detail

The Lago and X‐Ray capable Lago X optical imaging systems provide a powerful and flexible in-vivo imaging capability suitable for imaging cores, specialist researchers and small teams, delivering an unmatched 10 mouse capacity across BLI, FLI and X‐Ray.

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey